ONC (BeOne Medicines) Total Liabilities: $3,793 Mil (As of Mar. 2026)

What is BeOne Medicines Total Liabilities?

BeOne Medicines ONC -1.73% 81 Total Liabilities is $3,793 Mil as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $366.06 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BeOne Medicines's Total Liabilities for the quarter that ended in Mar. 2026 was $3,793 Mil.

BeOne Medicines's quarterly Total Liabilities increased from Sep. 2025 ($3,503.26 Mil) to Dec. 2025 ($3,827.38 Mil) but then declined from Dec. 2025 ($3,827.38 Mil) to Mar. 2026 ($3,793.18 Mil).

BeOne Medicines's annual Total Liabilities increased from Dec. 2023 ($2,267.95 Mil) to Dec. 2024 ($2,588.69 Mil) and increased from Dec. 2024 ($2,588.69 Mil) to Dec. 2025 ($3,827.38 Mil).

BeOne Medicines Total Liabilities Related Terms

BeOne Medicines Total Liabilities Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Total Liabilities Chart

BeOne Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

2,402.96

1,995.94

2,267.95

2,588.69

3,827.38

BeOne Medicines Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															2,342.01	2,527.92	3,503.26	3,827.38	3,793.18

81GF Score

BeOne Medicines Ltd ONC

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BeOne Medicines Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BeOne Medicines's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1828.83	+	(1014.853	+	883.338
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	82.188	+	18.17	+	0)
	=	3,827

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	8188.573	-	4361.194
	=	3,827

BeOne Medicines's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1811.51	+	(1012.185	+	866.629
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	84.59	+	18.263	+	0)
	=	3,793

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	8553.619	-	4760.442
	=	3,793

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $3,793 Mil mean?

BeOne Medicines (ONC) has a Total Liabilities of $3,793 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BeOne Medicines and its competitors.

Is BeOne Medicines' Total Liabilities too high?

BeOne Medicines' current Total Liabilities is $3,793 Mil. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does BeOne Medicines' Total Liabilities compare to MRNA and RPRX?

BeOne Medicines' Total Liabilities of $3,793 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BeOne Medicines and its competitors. BeOne Medicines's current Total Liabilities is $3,793 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BeOne Medicines stock overvalued right now?

Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $284.97 — trading 22.2% below its estimated fair value. The current Total Liabilities is $3,793 Mil. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Total Liabilities is $3,793 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $284.97 is trading 22.2% below its estimated GF Value™ of $366.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

Total Liabilities: $3,793 Mil
GF Value™: $366.06 vs. price of $284.97 (22.2% below fair value)
GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Industry Healthcare Biotechnology

Comparable Companies MRNA RPRX ROIV BNTX INCY INSM RVMD ALNY ASND JAZZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL XKRX:068270 HKSE:02269 HKSE:01801 OCSE:GMAB

Other Exchanges BEIGF:USA 06160:Hong Kong 49BA:Germany 688235:China B1ME34:Brazil

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website https://www.beonemedicines.com

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

81GF Score

Get the complete analysis for ONC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$284.97

Price

$366.06

GF Value

View ONC Analysis

See Total Liabilities data for all stocks →